De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis

Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.BACKGROUNDPhase II and observational studies support the use of rituximab in multiple sclerosis. Standard...

Celý popis

Podrobná bibliografia

Vydané v:	Multiple sclerosis Ročník 27; číslo 8; s. 1230
Hlavní autori:	Disanto, Giulio, Ripellino, Paolo, Riccitelli, Gianna C, Sacco, Rosaria, Scotti, Barbara, Fucili, Anita, Pravatà, Emanuele, Kuhle, Jens, Gobbi, Claudio, Zecca, Chiara
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	01.07.2021
ISSN:	1477-0970, 1477-0970
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!